Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals

Host Immune Response to Infection and Cancer: Unexpected Commonalities

(2014) Romina S. Goldszmid et al.   Cell Host & Microbe

Direct Effect of Bevacizumab on Glioblastoma Cell Lines In Vitro

(2014) Thomas Simon et al.   NEUROMOLECULAR MEDICINE

The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting

(2013) Miriam Merad et al.   Annual Review of Immunology

Tumor cell response to bevacizumab single agent therapy in vitro

(2013) Melanie Hein et al.   Cancer Cell International

Bevacizumab for the treatment of glioblastoma

(2013) Sajeel Chowdhary et al.   Expert Review of Neurotherapeutics

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges

(2013) Gazanfar Rahmathulla et al.   OncoTargets and Therapy

Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells

(2011) L. von Baumgarten et al.   CLINICAL CANCER RESEARCH

Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

(2011) Wolfgang Wick et al.   Current Neurology and Neuroscience Reports

Nomenclature of monocytes and dendritic cells in blood

(2010) L. Ziegler-Heitbrock et al.   BLOOD

Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo

(2010) Weijun Wang et al.   JOURNAL OF NEUROSURGERY

Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma

(2010) Ruman Rahman et al.   Journal of Oncology

Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1

(2009) C. Folkins et al.   CANCER RESEARCH

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Mode of action and clinical impact of VEGF signaling inhibitors

(2009) Jens Soltau et al.   Expert Review of Anticancer Therapy

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2008) A. Desjardins et al.   CLINICAL CANCER RESEARCH

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma

(2008) Richard G Everson et al.   Expert Review of Anticancer Therapy

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

(2008) J. Ma et al.   MOLECULAR CANCER THERAPEUTICS